Basket | Login | Register

 
 
 
 

Hungary

2012: National Dementia Strategies (diagnosis, treatment and research)

Issues relating to medical treatment

The availability of medicines in general

In Hungary, in-patient medicines are free of charge. Some pharmaceutical drugs are subsidised by the National Health Insurance Fund (Egészségbiztosítási Pénztár) at various levels of reimbursement.  This amounts to 100% of the price for certain chronic diseases and patients just have to pay a packing fee of HUF 300 (approx. EUR 0.95). Elderly people with low income and disabled persons can receive a special card which gives them a right to free medicines[1].

The availability of Alzheimer treatments

Except for galantamine, AD drugs are available in Hungary

Conditions surrounding the prescription and reimbursement of AD drugs

The available AD drugs are part of the reimbursement system (50% reimbursement). Prescriptions both for treatment initiation and for treatment continuation need to be filled in by specialist doctors. There are no restrictions as to the access of people living alone or in nursing homes to available Alzheimer treatments but continuous treatment must be guaranteed.

Since 1999, there have been several national guidelines for the diagnosis and treatment of Alzheimer’s disease. The 2006 guideline was accepted by the Ministry of Health and prescribes a number of diagnostic examinations (MMSE, Laboratory tests and either a CT or MRI scan).

Since 2003, special dementia centres have been instituted (at the time of print, the number of these centres was 84) which are led by neurologists or psychiatrists. Physicians of these centres have the right to prescribe donepezil, rivastigmine and memantine with reimbursement.

Prescription and reimbursement

Donepezil

Rivastigmine

Galantamine

Memantine

Available

Yes

Yes

No

Yes

Reimbursed

Yes

Yes

No

Yes

Initial drug reimbursed if prescribed by

Specialist

Specialist

Specialist

Specialist

Continuing treatment reimbursed if prescribed by

Specialist

Specialist

Specialist

Specialist

Required examinations

According to guidelines

According to guidelines

According to guidelines

According to guidelines

MMSE limits

26-10

26-10

 

18-0

Issues relating to research

Hungary is involved in the EU Joint Programme – Neurodegenerative Disease Research (JPND) and is a Collaborator in the Joint Action “Alzheimer Cooperative Valuation in Europe (ALCOVE)”.

[1] European Commission (2012): MISSOC – Mutual information system on social protection : Social protection in the Member States of the European Union, of the European Economic Area and in Switzerland : Comparative tables

 

 
 

Last Updated: Tuesday 14 May 2013

 

 
  • Acknowledgements

    The above information was published in the 2012 Dementia in Europe Yearbook as part of Alzheimer Europe's 2012 Work Plan which received funding from the European Union in the framework of the Health Programme. Alzheimer Europe gratefully acknowledges the support it has received from the Alzheimer Europe Foundation for the preparation and publication of its 2012 Yearbook.
  • European Union
 
 

Options